This page is used for Login Customizer plugin. It will not be visible to your readers. Do not delete it.
- Tollys presents scientific data supporting preclinical proof of concept for TL-532, its cancer immunotherapy drug candidate
- Tollys earns ‘Best-in-class therapeutic innovation’ award from MATWIN for its drug candidate TL-532
- Tollys appoints Amina Zinaï, MD, as head of clinical development
- Tollys welcomes Dr. Jean-Pierre Armand as member of its scientific advisory board
- Tollys appoints Philippe Goupit as chairman of the board